NASDAQ:MESO Mesoblast (MESO) Stock Price, News & Analysis $10.18 -0.15 (-1.45%) (As of 11/21/2024 ET) Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Mesoblast Stock (NASDAQ:MESO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mesoblast alerts:Sign Up Key Stats Today's Range$9.99▼$10.2550-Day Range$6.10▼$11.7152-Week Range$1.61▼$12.18Volume227,590 shsAverage Volume758,058 shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingBuy Company OverviewMesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More… I've got news for you… (Ad)Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman Mesoblast Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks27th Percentile Overall ScoreMESO MarketRank™: Mesoblast scored higher than 27% of companies evaluated by MarketBeat, and ranked 828th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingMesoblast has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMesoblast has only been the subject of 3 research reports in the past 90 days.Read more about Mesoblast's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mesoblast are expected to grow in the coming year, from ($0.74) to ($0.57) per share.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.22% of the outstanding shares of Mesoblast have been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Mesoblast has recently increased by 11.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.22% of the outstanding shares of Mesoblast have been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Mesoblast has recently increased by 11.20%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.54 News SentimentMesoblast has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Mesoblast this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for MESO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows7 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.43% of the stock of Mesoblast is held by institutions.Read more about Mesoblast's insider trading history. Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address MESO Stock News HeadlinesMesoblast Announces Director Change and ShareholdingsNovember 18 at 5:51 PM | markets.businessinsider.comMesoblast Limited’s AGM Resolutions Gain Strong ApprovalNovember 16, 2024 | markets.businessinsider.comBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. November 21, 2024 | WealthPress (Ad)Mesoblast Limited Advances in Drug Development and CommercializationNovember 15, 2024 | markets.businessinsider.comMesoblast Limited Outlines Future Strategies and Growth ProspectsNovember 15, 2024 | markets.businessinsider.comBuy Rating for Mesoblast Driven by Promising Market Opportunities and Upcoming PDUFA Date for RyoncilNovember 8, 2024 | markets.businessinsider.comHealth Check: PharmX has 99pc share of pharmacy market but reckons it has prescription for growthOctober 31, 2024 | msn.comAppendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024October 30, 2024 | globenewswire.comSee More Headlines MESO Stock Analysis - Frequently Asked Questions How have MESO shares performed this year? Mesoblast's stock was trading at $2.20 at the start of the year. Since then, MESO stock has increased by 362.7% and is now trading at $10.18. View the best growth stocks for 2024 here. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) posted its earnings results on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06. The company had revenue of $2.14 million for the quarter, compared to analyst estimates of $2 million. When did Mesoblast's stock split? Mesoblast's stock reverse split on Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. When did Mesoblast IPO? Mesoblast (MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. Who are Mesoblast's major shareholders? Mesoblast's top institutional investors include Jane Street Group LLC (0.07%), Lazari Capital Management Inc. (0.04%), XY Capital Ltd (0.03%) and Creative Planning (0.02%). How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings8/30/2023Today11/21/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CUSIPN/A CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$11.50 High Stock Price Target$12.00 Low Stock Price Target$11.00 Potential Upside/Downside+13.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.21 Current Ratio1.18 Quick Ratio1.18 Sales & Book Value Annual Sales$5.90 million Price / Sales197.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.21 per share Price / Book2.42Miscellaneous Outstanding Shares114,180,000Free Float92,713,000Market Cap$1.16 billion OptionableOptionable Beta3.47 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:MESO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.